(Q53580421)

15 May 2018

meta-analysis

0 references

title

Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening. (English)

1 reference

15 May 2018

alpha-1-antitrypsin deficiency

1 reference

1 reference

2

Ignacio Blanco

1 reference

15 May 2018

author name string

Frederick J de Serres

series ordinal

1

1 reference

15 May 2018

Enrique Fernández-Bustillo

series ordinal

3

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 August 2006

1 reference

15 May 2018

COPD: Journal of Chronic Obstructive Pulmonary Disease

published in

1 reference

15 May 2018

volume

3

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

page(s)

133-139

1 reference

15 May 2018

What we owe to alpha(1)-antitrypsin and to Carl-Bertil Laurell

cites work

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

PI SZ phenotype in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Genetic epidemiology of alpha‐1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Antitrypsin and emphysema. Perspective and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Smoking, lung function, and alpha 1-antitrypsin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Genetics and respiratory disease. 2. Alpha 1-antitrypsin deficiency, cirrhosis and emphysema

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

The mechanism of Z alpha 1-antitrypsin accumulation in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Alpha-1 antitrypsin in childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Relation of Protease Inhibitor Phenotypes to Obstructive Lung Diseases in a Community

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Statistics notes. The odds ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

The protease inhibitor PI*S allele and COPD: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

Familial prevalence of chronic obstructive pulmonary disease in a matched pair study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F15412550600829257

10.1080/15412550600829257

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018